RT Journal Article
SR Electronic
T1 Evaluating Digital Device Technology in Alzheimer’s Disease via Artificial Intelligence
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.07.21265705
DO 10.1101/2021.11.07.21265705
A1 Sood, Meemansa
A1 Aborageh, Mohamed
A1 Domingo-Fernández, Daniel
A1 Harms, Robbert
A1 Lordick, Thomas
A1 Birkenbihl, Colin
A1 Owens, Andrew P
A1 Coello, Neva
A1 Narayan, Vaibhav A.
A1 Aarsland, Dag
A1 Bügler, Maximilian
A1 Fröhlich, Holger
A1 ,
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/11/16/2021.11.07.21265705.abstract
AB The use of digital technologies may help to diagnose Alzheimer’s Disease (AD) at the pre-symptomatic stage. However, before implementation into clinical practice, digital measures (DMs) need to be evaluated for their diagnostic benefit compared to established questionnaire-based assessments, such as the Mini-Mental State Examination (MMSE) for cognition and Functional Activity Questionnaire (FAQ) for daily functioning. Moreover, the quantitative and qualitative relationship of DMs to these well understood scores needs to be clarified to aid interpretation. In this work we analyzed data from 148 subjects, 58 cognitively normal and 90 at different stages of the disease, which had performed a smartphone based virtual reality game to assess cognitive function. In addition, we used clinical data from Alzheimer’s Disease Neuroimaging Initiative (ADNI). We employed an Artificial Intelligence (AI) based approach to elucidate the relationship of DMs to questionnaire-based cognition and functional activity scores. In addition, we used Machine Learning (ML) and statistical methods to assess the diagnostic benefit of DMs compared to questionnaire-based scores. We found non-trivial relationships between DMs, MMSE, and FAQ which can be visualized as a complex network. DMs, in particular those reflecting scores of individual tasks in the virtual reality game, showed a better ability to discriminate between different stages of the disease than questionnaire-based methods. Our results indicate that DMs have the potential to act as a crucial measure in the early diagnosis and staging of AD.Competing Interest StatementMB and RH are employees of Altoida Inc. and Altoida AG. NC is an employee of Novartis Pharmaceuticals AG. None of the employers had any influence on the scientific content of this study.Funding StatementInnovative Medicines Initiative Joint Undertaking under grant agreement #IMI2-2017-12-01Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The New England Independent Review Board (NEIRB) gave the approval on 17 October 2016. IRB reference#: 120160894I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe respective data owners of the data used in this publication provided access to the datasets. For ADNI, approval was received by applying for data access on http://adni.loni.usc.edu/data-samples/access-data/ web server. For Altoida, approval to use the data was provided by it’s data owners. http://adni.loni.usc.edu/data-samples/access-data/